Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
The First-Line Pancreatic Cancer Patient Population Will Experience A Dynamic Change
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2400927" data-attributes="member: 124445"><p>Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds although the pancreatic cancer drug market will remain relatively flat through 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, the first-line patient population will experience a dynamic change in treatment practice owing to increased uptake of the cytotoxic regimen, FOLFIRINOX and the approval and launch of Celgene's Abraxane as an add-on to Eli Lilly's Gemzar...<a href="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/Y0z9S-iFbVU" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/Y0z9S-iFbVU/3MP8" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2400927, member: 124445"] Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds although the pancreatic cancer drug market will remain relatively flat through 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, the first-line patient population will experience a dynamic change in treatment practice owing to increased uptake of the cytotoxic regimen, FOLFIRINOX and the approval and launch of Celgene's Abraxane as an add-on to Eli Lilly's Gemzar...[URL="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/0/da"][IMG]http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/1/da"][IMG]http://feedads.g.doubleclick.net/~a/NGA9m4xV3xNmVztGYqZSV4l7HK8/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/Y0z9S-iFbVU[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/Y0z9S-iFbVU/3MP8]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top